Neurology News with information about conditions, treatments, current studies and breakthroughs.
Daily Step Count Linked to Dementia Risk
According to a new study, walking between 3,800 to 9,800 steps a day can reduce your risk of mental decline. [...]
TMS for Depression – Patient Success Story
TMS can be used to treat depression in patients with treatment-resistant depression. In recent clinical studies, a third of patients [...]
Brain Gym – Simple Brain Exercises
It is equally important to exercises our bodies as well as our brains. Here are some simple exercises that can [...]
Colorful Produce Can Help Curb Memory Loss
Studies have found that eating colorful fruits and vegetables can help keep your memory sharp! Watch the below video for [...]
Benign Paroxysmal Positional Vertigo (BPPV)
Benign paroxysmal positional vertigo (BPPV) is a problem in the inner ear. It is the most common cause of vertigo, [...]
TMS for Tinnitus
Tinnitus, or ringing in the ears, impacts some 21 million adults in the United States. Tinnitus can also cause anxiety, [...]
- Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias June 12, 2026New JAMA Publication! Congratulations to Dimitry S. Davydow, MD, MPH, Gregory M. Pontone, MD, MHS, Michael S. Okun, MD, and Melissa J. Armstrong, MD on their publication “Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias,” which appears in JAMA Open Network. Long-term exposure to common air pollutants may increase the risk of developing Parkinson’s disease-related dementia and Lewy body dementia, according to…
- Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results June 10, 2026Congratulations Dr. Irene Malaty Dr. Malaty research “Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results,” was published in the May 2026 issue of Neurology and Therapy. Abstract Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on…
- Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease June 8, 2026New Publication! Congratulations to Drs. Melissa J Armstrong, Nikolaus R. McFarland, Michael Okun and David Vaillancourt on the publication of “Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease,” which appears in the May edition of Annals of Neurology. Abstract Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people…
- Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review June 5, 2026Congratulations on your new publication! Congratulations to Hector David Meza Comparan, Luciola Frota, Michael Mathelier, Carolina Maciel and Katharina Busl on the publication of “Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review,” which appears in the April 8th edition of Neurology. Abstract Objective: To evaluate the extent and…
Get Social